Compare EARN & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | PEPG |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 179.4M |
| IPO Year | 2012 | 2022 |
| Metric | EARN | PEPG |
|---|---|---|
| Price | $3.62 | $2.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $4.50 | ★ $10.19 |
| AVG Volume (30 Days) | 499.9K | ★ 936.2K |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | ★ 26.82% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.22 | $1.31 |
| 52 Week High | $5.72 | $7.80 |
| Indicator | EARN | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 45.94 |
| Support Level | $3.22 | $2.24 |
| Resistance Level | $4.45 | $2.62 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 72.73 | 32.20 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.